Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Study Plans Would Be Required At End Of Phase II Under Bipartisan House Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

Rather than assessing monetary penalties for violating study deadlines, H.R. 4274 directs FDA to issue warning letters and publish them on its website.

You may also be interested in...

Would Sponsors Do Earlier Pediatric IBD Studies With Nod From Agency Or Advisory Committee?

Including adolescents in adult studies was one option for obtaining information on inflammatory bowel disease therapies’ efficacy and safety in children discussed at a two-day FDA and professional society workshop.

Pediatric IBD Studies Should Assess Disease Activity, Panel Says

Clinicians tell FDA that focusing solely on symptoms as an endpoint for pediatric ulcerative colitis and Crohn’s disease ignores the long-term deleterious effects of inflammation. Panel stresses the need to include growth as an endpoint and to conduct pediatric studies earlier.

Pediatric Reauthorization In Senate Hits Pothole From Cost Offset For Exclusivity

A BPCA/PREA reauthorization bill in the Senate is similar to a bi-partisan House bill that has been incorporated into House Energy and Commerce Committee Republicans’ discussion draft of comprehensive user fee legislation, but Senate HELP committee drafters appear to need to find a “pay-for” before including the provisions.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts